Safety of Insulin Degludec/Insulin Aspart in Patients with Diabetes Mellitus over a Period of 1 Year during Routine Clinical Care in India: SMART (Study of Management of Diabetes with Ryzodeg™ Treatment)

Safety of Insulin Degludec/Insulin Aspart in Patients with Diabetes Mellitus over a Period of 1 Year during Routine Clinical Care in India: SMART (Study of Management of Diabetes with Ryzodeg™ Treatment)

This post-authorization study was conducted to evaluate the safety of insulin degludec/insulin aspart (IDegAsp) in adult patients with diabetes mellitus (DM) during routine clinical care under a real-world setting in India. Eligible patients received IDegAsp for a minimum of 12 months during routine...

Full description

Bibliographic Details
Main Authors: Jothydev Kesavadev, Ambanna Gowda, Harish Kumar, Sadasiva Rao Yalamanchi, Sailesh Lodha, Kiran Pal Singh, Debasis Basu, Arthur Asirvatham, Navneet Shah, Muzammil Khan Pathan, Manjunatha Revanna, Jagat Jyoti Mukherjee
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Medical Sciences
Subjects:
diabetes mellitus
glycemic control
IDegAsp
India
insulin therapy
safety
Online Access:https://www.mdpi.com/2076-3271/10/1/1

Similar Items

Similar Items